In a major breakthrough, Dr. Rashmi Rana and her team from Sir Ganga Ram Hospital in New Delhi have made significant progress in understanding pulmonary arterial hypertension (PAH).
This serious condition causes high blood pressure in the lungs’ arteries, leading to heart failure and low oxygen levels in the blood.
Dr. Rana’s team studied the genetic activity of PAH patients and compared it with healthy individuals. They discovered four specific genes—SNORD3D, HLA-AS1, EGR1, and NPM1—that are less active in PAH patients. This finding helps us understand the disease better.
These genes, previously overlooked, could also play a crucial role in PAH. Dr. Rana said, “Our study offers new insights into PAH. By focusing on these genes, we can develop targeted treatments and better diagnostic tools.”
PAH is hard to diagnose and treat because there are no specific tests, and it’s often found too late. Current treatments mainly manage symptoms instead of addressing the disease’s root causes.
Dr. Rana’s discovery opens new possibilities for treatment. By targeting the identified genes, researchers and pharmaceutical companies could create therapies that address the genetic issues causing PAH.
This could lead to more effective and personalized treatments. The discovery could also lead to new tests that detect PAH earlier and more accurately.
As research continues, there’s growing hope in the medical community. Personalized medicine, which tailors treatments to individual genetic profiles, could soon become a reality for PAH patients.
Read Also – Can Obesity Lead To Heart Failure? Experts Share Insights
This progress offers new hope for better outcomes and improved quality of life for those with PAH. Dr. Rana’s work is a significant step forward in the fight against PAH. With continued research, we can look forward to better diagnostics and treatments, bringing new hope to Pulmonary Arterial Hypertension (PAH) patients worldwide.
